E-LIB Suche - Ergebnisse für: San-Miguel, Jesus

1

Mapping global forest cover of the year 2020 to support the..

EUR, 31888

Bourgoin, Clement ; Ameztoy, Iban ; Verhegghen, Astrid... , 2024

2

Practical Aspects of Immunotherapy: A Report from the 20th ..:

Raje, Noopur S. ; Cohen, Adam D. ; Patel, Krina K....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 6 - p. 350-357 , 2024

Link: https://doi.org/10.1016/..

3

The 2022 COPERNICUS emergency management service general as..:

Ceccato, Pietro ; Moreira Agrela Gonçalves, Andre ; Pekel, Jean-François... , 2023

Link: https://data.europa.eu/d..

4

P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD..:

Wong, Sandy W. ; Bar, Noffar ; Victoria Mateos, María...
HemaSphere. 7 (2023) S3 - p. e1220745 , 2023

Link: https://doi.org/10.1097/..

5

POSTER: MM-162 Durability of Responses With Biweekly Dosing..:

Usmani, Saad Z ; Karlin, Lionel ; Benboubker, Lotfi...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S224 , 2023

Link: https://doi.org/10.1016/..

6

OA-20 Genomic profiling of high-risk smoldering myeloma pat..:

Medina, Alejandro ; Vázquez, Iria ; Cuenca, Isabel...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S12-S13 , 2023

Link: https://doi.org/10.1016/..

7

Towards an Integrated Approach to Wildfire Risk Assessment:..:

Chuvieco, Emilio ; Yebra, Marta ; Martino, Simone...
Fire. 6 (2023) 5 - p. 215 , 2023

Link: https://doi.org/10.3390/..

8

P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD..:

Costa, Luciano ; Bar, Noffar ; Mateos, Maria-Victoria...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S52-S53 , 2023

Link: https://doi.org/10.1016/..

9

Oral Abstract: MM-304 Efficacy Outcomes and Characteristics..:

Munshi, Nikhil ; Pavia, Bruno ; Martin, Thomas...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S146 , 2023

Link: https://doi.org/10.1016/..

10

P-367 High-risk cytogenetic abnormalities in multiple myelo..:

Rodriguez-Otero, Paula ; Gonzalez-Calle, Veronica ; Calasanz, Maria-Jose...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S241-S242 , 2023

Link: https://doi.org/10.1016/..

11

Impact of treatment effect on MRD and PFS: an aggregate dat..:

Paiva, Bruno ; Zherniakova, Anastasiia ; Nuñez-Córdoba, Jorge M....
Blood Advances. 8 (2023) 1 - p. 219-223 , 2023

Link: https://doi.org/10.1182/..

12

P-079 Impact of treatment effect on measurable residual dis..:

Paiva, Bruno ; Zherniakova, Anastasiia ; Nuñez, Jorge...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S78 , 2023

Link: https://doi.org/10.1016/..

13

Disease Monitoring In Multiple Myeloma:

Hillengass, Jens ; Martin, Tom ; Puig, Noemi...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 4 - p. 244-248 , 2023

Link: https://doi.org/10.1016/..

14

OA-12 Predictors of unsustained measurable residual disease..:

Guerrero, Camila ; Puig, Noemi ; Cedena, Teresa...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S7-S8 , 2023

Link: https://doi.org/10.1016/..

15

Phase 1b Study of Isatuximab in Combination With Bortezomib..:

Ocio, Enrique M. ; Bringhen, Sara ; Martinez-Lopez, Joaquin...
HemaSphere. 7 (2023) 2 - p. e829 , 2023

Link: https://doi.org/10.1097/..